Indoco Remedies Ltd Upgraded to Sell on Technical Improvements and Valuation Shift

Technical Trends Drive Upgrade

The primary catalyst for the upgrade lies in the technical analysis of Indoco Remedies’ stock. The technical grade has improved from mildly bullish to bullish, signalling a more positive momentum in price action. Key indicators such as the Moving Average Convergence Divergence (MACD) show a weekly mildly bearish stance but a monthly mildly bullish trend, suggesting a potential shift in medium-term momentum.

Further supporting this upgrade, the Relative Strength Index (RSI) remains neutral with no clear signal on both weekly and monthly charts, indicating the stock is neither overbought nor oversold. Bollinger Bands have turned bullish on both weekly and monthly timeframes, reflecting increased volatility with upward price pressure. Daily moving averages are bullish, reinforcing short-term strength.

Other technical tools present a mixed but improving picture: the Know Sure Thing (KST) indicator is bullish weekly but bearish monthly, while Dow Theory assessments are mildly bullish across both weekly and monthly periods. On-Balance Volume (OBV) is mildly bullish weekly but shows no trend monthly, suggesting cautious accumulation by investors.

These technical signals collectively underpin the upgrade in the technical grade, indicating that the stock’s price momentum is gaining traction after a period of subdued performance.

Valuation Moves from Attractive to Fair

Alongside technical improvements, Indoco Remedies’ valuation grade has shifted from attractive to fair. The company currently trades at a price-to-book value of 2.41 and an enterprise value to EBITDA ratio of 20.11, which, while elevated, is more reasonable compared to its peers in the pharmaceuticals sector. The price-to-earnings (PE) ratio stands at a negative -30.89, reflecting recent losses and earnings volatility.

Return on Capital Employed (ROCE) is low at 0.77%, and Return on Equity (ROE) is negative at -9.82%, underscoring weak profitability. Dividend yield remains minimal at 0.08%, indicating limited income return for investors. Despite these challenges, the stock’s valuation is less stretched than several competitors such as Wockhardt and Sai Life Sciences, which are rated very expensive with PE ratios exceeding 80 and EV/EBITDA multiples above 40.

This fair valuation status suggests that while Indoco Remedies is not undervalued, it is trading at a discount relative to many peers, offering some cushion for investors considering the risk-reward balance.

Financial Trends Remain Weak

Despite the upgrade in technical and valuation grades, Indoco Remedies’ financial trend continues to deteriorate. The company has reported negative results for 15 consecutive quarters, with operating profits declining at a compounded annual growth rate (CAGR) of -28.83% over the past five years. This sustained underperformance has contributed to a downgrade in the overall Mojo Grade from Strong Sell to Sell, reflecting ongoing fundamental concerns.

Debt metrics remain a significant concern. The debt-to-EBITDA ratio is high at 7.69 times, indicating a heavy debt burden relative to earnings. The debt-equity ratio has risen to 1.16 times, the highest in recent periods, signalling increased leverage risk. Interest expenses have surged by 47.83% over the last six months to ₹74.21 crores, further pressuring profitability.

Operational efficiency also shows strain, with the debtors turnover ratio at a low 3.67 times, suggesting slower collection cycles and potential working capital challenges. The company’s average ROE of 7.83% over time points to low returns on shareholder funds, dampening investor confidence.

Stock Performance Versus Benchmark

Indoco Remedies’ stock price has exhibited mixed returns relative to the Sensex benchmark. Over the past week and month, the stock outperformed the Sensex with returns of 10.14% and 9.01% respectively, compared to the Sensex’s -0.36% and 0.65%. Year-to-date, the stock has gained 5.90%, while the Sensex declined by 9.34%, indicating some recent resilience.

However, longer-term performance remains disappointing. The stock has lost 9.47% over the last year against a Sensex decline of 3.52%, and over three and five years, it has underperformed significantly with losses of 23.07% and 44.77% respectively, while the Sensex gained 18.87% and 37.67%. Over a decade, the stock is down 19.80% compared to the Sensex’s robust 178.11% gain.

This persistent underperformance highlights the company’s struggle to generate sustained shareholder value despite recent technical improvements.

Quality Assessment and Outlook

Indoco Remedies’ quality grade remains low, consistent with its Sell rating. The company’s weak long-term fundamentals, including negative operating profit growth and poor return metrics, continue to undermine its investment appeal. The promoter holding remains majority, but this has not translated into improved operational or financial performance.

While the recent technical upgrade offers some optimism for short-term price momentum, the fundamental weaknesses and financial risks suggest caution. Investors should weigh the fair valuation and improving technical signals against the company’s persistent earnings challenges and leverage concerns.

Conclusion

The upgrade of Indoco Remedies Ltd’s investment rating from Strong Sell to Sell reflects a modest improvement in technical indicators and a more balanced valuation perspective. However, the company’s financial trend remains negative, with ongoing losses, high debt levels, and underwhelming returns on capital. The stock’s recent outperformance relative to the Sensex in the short term is encouraging but does not offset the long-term underperformance and fundamental risks.

Investors should approach Indoco Remedies with caution, recognising that while momentum may be building, the company’s core financial health and profitability require significant improvement to justify a more positive rating.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today